Grant: Canada Postdoctoral Research Award (CPRA) program
University of Calgary
$140,000.00
Towards investigating the role of ALKAL2-ALK signaling in trigeminal sensitization associated with migraine
FY 2025-26
Summary
Migraine is a prevalent chronic neurovascular disorder that significantly affects both individuals and society and is characterized by recurrent and often debilitating episodes of intense headache, nausea, vomiting, and heightened sensitivity to light and sound. These episodes can persist for 4 to 72 hours and are accompanied by various physical, cognitive, and psychological symptoms. Globally, migraine has been identified as the leading cause of disability among individuals under 50 years old. The headache pain experienced during a migraine episode, which affects different regions of the brain, results from the activation of the trigeminovascular system which consists of specific nerves. Given the limited treatment options for chronic pain conditions, including migraine, there is a need to reassess the mechanisms that are involved in the activation of these nerves and consequently migraine pain.
Recent studies have reported the role of a specific group of enzymes called receptor tyrosine kinases (RTKs) in persistent pain conditions. The Zamponi and Altier laboratory have uncovered the role played by one of these TRKs called ALK and a molecule called ALKAL2 that causes its activation, in persistent pain. Our recent findings suggest that ALKAL2-ALK signaling plays a role in pain associated with both inflammation and migraine pain. We will now build on these exciting preliminary findings and a considerable body of published work from the Zamponi, Altier, and other labs to elucidate the contribution of ALKAL2 to the nerves involved in migraine pain, and evaluate how we can use this information to design safer avenues for treating migraine, a common chronic condition.
Department
Program
Canada Postdoctoral Research Award (CPRA) program
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
536815
Name
Kamau Peter M
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Towards investigating the role of ALKAL2-ALK signaling in trigeminal sensitization associated with migraine
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Alk Receptor Ligands; Alkal2-Alk Signaling; Chronic Pain; Electrophysiological Properties; Headaches; Migraine; Migraine Models; Trigeminal Nociceptors; Trigeminal Sensitization
Abstract
Migraine is a prevalent chronic neurovascular disorder that significantly affects both individuals and society and is characterized by recurrent and often debilitating episodes of intense headache, nausea, vomiting, and heightened sensitivity to light and sound. These episodes can persist for 4 to 72 hours and are accompanied by various physical, cognitive, and psychological symptoms. Globally, migraine has been identified as the leading cause of disability among individuals under 50 years old. The headache pain experienced during a migraine episode, which affects different regions of the brain, results from the activation of the trigeminovascular system which consists of specific nerves. Given the limited treatment options for chronic pain conditions, including migraine, there is a need to reassess the mechanisms that are involved in the activation of these nerves and consequently migraine pain.
Recent studies have reported the role of a specific group of enzymes called receptor tyrosine kinases (RTKs) in persistent pain conditions. The Zamponi and Altier laboratory have uncovered the role played by one of these TRKs called ALK and a molecule called ALKAL2 that causes its activation, in persistent pain. Our recent findings suggest that ALKAL2-ALK signaling plays a role in pain associated with both inflammation and migraine pain. We will now build on these exciting preliminary findings and a considerable body of published work from the Zamponi, Altier, and other labs to elucidate the contribution of ALKAL2 to the nerves involved in migraine pain, and evaluate how we can use this information to design safer avenues for treating migraine, a common chronic condition.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Kamau, Peter M
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~